Introduction
Calcium channel blockers (CCB) are commonly implicated in episodes of severe poisoning that result in cardiovascular collapse; case fatality is high, despite supportive treatment including fluid resuscitation, intravenous calcium, inotropes, vasopressors and high-dose insulin therapy. 1, 2 The American Association of Poison Control Centers (AAPCC) reported that in 2008 in the USA, there were 10,398 exposures to CCBs, resulting in 12 deaths and 63 major adverse outcomes; 1,430 of the 10,398 exposures (13.7% of reported cases) occurred in children younger than six years of age. 3 Felodipine is a lipid-soluble dihydropyridine CCB with a long half-life. It is used for the treatment of hypertension. 1 By antagonising L-type calcium channels, it reduces calcium influx leading to vascular smooth muscle relaxation and arterial vasodilation. 3 Although dihydropyridines have minimal direct cardiac actions in therapeutic doses, atrioventricular block and cardiac depression may occur in overdose, as well as profound reduction in systemic vascular resistance. 1, 3 
Case report
A 16-year-old girl was brought to the emergency department approximately six hours after ingesting a mixed overdose reported to include felodipine modified-release tablets, 280 mg (3.3 mg/kg), doxazosin 28 mg (0.33 mg/kg), cinnarizine 210 mg (2.4 mg/kg), bendroflumethiazide 70 mg (0.81 mg/kg), flucloxacillin 3.5 g (41 mg/kg) and alcohol (unknown quantity). On examination she was pale, clammy, increasingly confused and combative, with marked hypotension (60/40 mm Hg) and sinus tachycardia (140-160 bpm).
Her blood pressure initially, but transiently, responded to drug and fluid therapy. However, after a total of 2,500 mL 0.9% sodium chloride, 10 mg glucagon, 20 mL 10% calcium chloride and 15 µg IV adrenaline, she remained agitated with hypotension (systolic blood pressure 60-80 mm Hg) necessitating repeated boluses of 5-10 µg intravenous adrenaline.
To permit further care, anaesthesia was induced with ketamine 0.8 mg/kg and suxamethonium 1.2 mg/kg, and her trachea was intubated uneventfully. Central venous and arterial lines were inserted.
Following intubation, blood pressure was initially stable at 90/60 mm Hg and heart rate remained approximately 150 bpm, but 30 minutes later her blood pressure began to fall again. A further 1000 mL 0.9% sodium chloride bolus, 5 mg glucagon, 10 mL 10% calcium chloride and 2 mg IV adrenaline were given without effect. After another 10 minutes, her systolic blood pressure was 45 mm Hg. Bedside echocardiography provided little further information as the study was limited by persistent tachycardia.
Infusions of adrenaline and noradrenaline, then vasopressin were commenced and rapidly titrated to doses of 0.62 µg/kg/min adrenaline, 0.62 µg/kg/min noradrenaline and 0.025 U/kg/hr vasopressin, but systolic blood pressure only improved to 80 mm Hg. In the meantime, a high-dose insulin infusion was being prepared.
The patient continued to deteriorate and cardiovascular collapse appeared imminent. Intravenous lipid emulsion (ILE) was readily available, so was given as an initial bolus of 1.5 mL/kg Intralipid ® 20%, followed by an infusion at 15 mL/kg/hr to a total of 1,000 mL (11.6 mL/kg) over 50 minutes. An improvement in blood pressure was seen within 5-10 minutes of the bolus and continued throughout the infusion, allowing discontinuation of the adrenaline infusion and a reduction in the noradrenaline infusion to 0.078 µg/kg/min. Due to the rapid improvement seen after starting ILE, the high-dose insulin infusion was not started. At the end of the ILE infusion, systolic blood pressure of 100-110 mm Hg was maintained. The noradrenaline and vasopressin infusions were discontinued within four and 16 hours respectively of commencing the ILE.
The clinical improvement was sustained and she was successfully extubated within 24 hours, with no ongoing requirement for cardiovascular support. Subsequently, the only
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other clinical feature of note during her stay in the intensive care unit (ICU) was polyuria, thought to be related to bendroflumethiazide ingestion and fluid resuscitation. She was discharged from the ICU within 72 hours of hospital admission with no neurological deficit or ongoing organ dysfunction.
Discussion
The substantial dose of felodipine ingested along with the clinical presentation suggests that felodipine was the principal agent responsible for the severe refractory hypotension observed in this case; however, the other drugs, including doxazosin, may have contributed.
Although at six hours post ingestion, significant drug redistribution may be expected for fat soluble drugs, maximum plasma concentrations occur 3-5 hours after therapeutic doses of modified release felodipine and a delay in peak concentrations would be expected after overdose. 4 Despite standard treatment for CCB toxicity, including fluid resuscitation, calcium, glucagon, catecholamines and vasopressin, the patient' s blood pressure continued to fall with imminent cardiovascular collapse. This progressive deterioration appears to have been reversed rapidly by the administration of ILE, an improvement that was sustained without the requirement for high-dose insulin therapy. The timing of this improvement with the administration of ILE provides circumstantial but compelling evidence of benefit from this therapy.
The benefit of ILE therapy was first demonstrated in the treatment of local anaesthetic toxicity in animal models by Weinberg et al in 1998. 5 It is now established in clinical practice, with substantial evidence of benefit shown in both animal and human studies. 6, 8 There is also an increasing body of animal and human evidence suggesting clinical benefit from ILE therapy for refractory toxicity caused by other lipophilic drugs, including tricyclic antidepressants and lipophilic betablockers. 6, 8, 9 For CCB poisoning, evidence suggesting benefit from ILE is available from animal studies involving verapamil, [10] [11] [12] [13] although this was not of greater benefit than that of high-dose insulin therapy 14 and no benefit was seen in one study of nifedipine toxicity. 15 Evidence of benefit in humans is limited to case reports demonstrating clinical improvement after use for verapamil toxicity 16 and mixed verapamil and atenolol 17 overdoses. We believe this to be the first reported use of ILE for the treatment of felodipine toxicity.
The mechanism by which ILE therapy produces its benefits remains uncertain. The 'lipid sink' hypothesis is that lipophilic toxins are removed from their site of action by sequestration into the increased plasma lipid pool. 18 If this is correct, ILE is a biologically plausible treatment for poisoning with felodipine, since felodipine is a lipid-soluble drug as evidenced by its Log P (octanol/water) coefficient of 3.86, higher than that of diltiazem (2.79), verapamil (3.8) and bupivacaine (3.4) . 19 Sequestration has been demonstrated in a case of verapamil overdose. 20 In this case, sequestration of co-ingestants may have also contributed to the improvement seen, as some of the co-ingestants also have Log P (octanol/water) coefficients greater than 1.0, (cinnarizine (5.8), doxazosin (2.09), and bendroflumethazide (1.9)). 19 However, because of the modest doses of these drugs, as well as their lack of propensity to cause severe hypotension, we believe that the contribution of these agents to the severe cardiovascular collapse was probably limited.
It has also been proposed that ILE administration may increase myocardial uptake and oxidation of free fatty acids which are the preferred substrate for myocardial oxidative phosphorylation, thus increasing ATP formation, energy delivery and contractility. 6 A review of 42 reported uses of ILE found only two reports of possible adverse effects; one case of hyperamylasaemia and one of acute lung injury, the aetiology of which was thought likely to be multifactorial. 9 High-dose insulin euglycaemic therapy (HIET) is also used to manage CCB toxicity. In poor perfusion states such as those encountered in CCB toxicity, myocardial cells utilise glucose rather than free fatty acids as their main energy source. Hypoperfusion impairs glucose delivery to cells and leads to relative insulin insufficiency. It is hypothesised that this situation is reversed by providing high levels of insulin. 6 Given this proposed mechanism at the cellular level, it is suggested that HIET should be started as early as possible. Our experience illustrates that it can take considerable time (in an already critical situation) to prepare and administer this therapy.
Intralipid is becoming more widely available in response to the AAGBI guidelines on local anaesthetic toxicity. 21, 22 Aside from the evidence about its efficacy, the need for minimal preparation and the ease with which it can be administered make it a very useful alternative to HIET in time-critical situations.
Our report, like many others suggesting benefit from ILE in human poisoning, is limited by the lack of analytical confirmation and the presence of multiple toxins. The conclusions that can be drawn from a single case report are limited but this case adds weight to the available circumstantial evidence of benefit for treating severe toxicity related to highly lipid-soluble drugs. As ILE appears relatively safe, we believe that its use in CCB poisoning refractory to conventional therapy is justified, but clinical outcomes, favourable or otherwise, should be reported. The website 'www.lipidrescue.org' provides a forum for communicating outcomes. 23
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